ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Recent Developments in Fighting Rare Diseases.

Updated on March 6, 2013

In a recent report that was published by the Pharmaceutical Research and Manufacturers of America (PhRMA); leading drug and research companies announced a shift in the focus of their research to find contemporary medications for a range of rare diseases that have fewer or no treatment options. The report indicated that they are running tests of more than 5,400 potential new medicines, including many being tested for multiple conditions and nearly 1,800 research projects are for rare diseases which may potentially improve the outlook for many of those patients.

There are nearly 7000 to 8000 known rare diseases worldwide, many with life-threatening outcomes. Until recently, pharmaceutical research companies did not willingly organize research on treatments for rare diseases; this is due to the limited number of patients for each condition and thus lack of profit motive. These diseases are often called orphan diseases to coin the fact that they are rare conditions.

Patients with rare diseases genuinely need a boost in medical advancement in this area as they still lack proper diagnostic tests and accordingly suffer delays in diagnosis and treatment. Therefore; it is believed that more quality research on these rare illnesses will provide patients with improved drug efficacy and fewer side effects. In the last decade the number of medicines for treating rare diseases increased to 140 per year compared to 64 per year in the previous decade.

The use of revolutionized genomic approaches like next generation sequencing (NGS) made it possible to analyze large panels of genes or whole genomes in a single run. It was already used for the diagnosis of rare disorders like neuorological diseases, retinitis pigmentosa and skeletal abnormalities. Recently; on the 24th of Jan 2013, the EU has announced 38 million Euro funding for research towards new treatments and for the development of a central global rare disease hub involving 70 institutions that will allow scientists to share data from their genomics research projects. These researchers will try to address rare neurodegenerative and neuromuscular disorders using next generation whole-exome sequencing.

Also on June 2012; the BGI, world\'s largest genomics organization, and The Children\'s Hospital of Philadelphia (CHOP) announced that they have jointly initiated the 1,000 rare diseases project with the aim of accelerating the discovery of genetic variants underlying rare diseases. Researchers on this project are using NGS technologies that are both cost effective and efficient. They are hoping to identify the genetic variants underlying rare diseases by using whole-genome sequencing which makes it possible to pinpoint the causes of many rare disorders using smaller number of patients samples.

The advance in DNA sequencing made it possible for an entire human genome to be sequenced within few days at a reasonable cost. This will undoubtedly pave the way for future research on personalized treatments for patients suffering rare diseases through interpreting both genetic and clinical data leading to more effective treatments and a better quality of life for patients.








    0 of 8192 characters used
    Post Comment

    No comments yet.


    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at: ""

    Show Details
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)